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Abstract
Background: Continued efforts are being directed toward the development of microbicides that will be used to
reduce or eliminate the risk of HIV-1 sexual transmission. Unfortunately, clinical trials involving polyanion-containing
microbicide formulations, including Carraguard (l-carrageenan [LC]) and Ushercell (cellulose sulfate [CS])
demonstrated that these products were ineffective and may have, in some circumstances, increased the risk of HIV-
1 infection. These findings prompted reassessments of the in vitro activities of these agents to determine whether
variables that can affect agent safety and efficacy had been overlooked during preclinical testing. One such
variable is product retention and loss following topical application.
Results: In the present studies involving an HIV-1-susceptible cell line and primary human immune cells, product
loss was mimicked by introducing and then removing polyanionic compounds prior to HIV-1 infection. In these in
vitro “washout” experiments, LC and CS significantly enhanced HIV-1 infection, despite potent antiviral activity
when introduced simultaneously with the virus. The presence and magnitude of this effect were dependent on
compound identity and concentration; target cell; interval between compound removal and virus challenge; and
coreceptor usage. Levels of enhancement (relative to controls) were considerable, exceeding a 200% increase (CS)
in P4-R5 MAGI cells and a 300% increase (LC) in human peripheral blood mononuclear cells.
Conclusions: These studies, which demonstrate significant increases in HIV-1 infection subsequent to application
and removal of LC and CS, support plausible explanations for the failures of microbicides formulated from these
compounds. Detailed studies are now underway to determine the mechanism responsible for this enhancement
effect and to assess the potential contribution of this effect to the clinical failures of these agents.
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Background
In the present AIDS pandemic, approximately 50% of the
33.4 million people infected with HIV-1 are women [1].
This fact highlights the urgent need for female-controlled
and female-centric prevention methods that can effec-
tively reduce or eliminate the risk of infection in women.
One response to this need is the development of safe and
effective topical microbicides, which are chemical entities
that, when applied prior to vaginal- or rectal-receptive
intercourse, will prevent the transmission of HIV-1 [2-6].
Numerous candidate microbicide compounds with varied
and diverse mechanisms of action are under preclinical
development. In addition, nu m e r o u sm i c r o b i c i d e sh a v e
been or are being evaluated in clinical trials for safety
and efficacy.
Among the potential microbicide agents advanced
through clinical trials were two compounds classified as
polyanions: carrageenan and cellulose sulfate (CS).
l-Carrageenan (LC) was thought to be especially promis-
ing as an antiviral agent because its demonstrated in
vitro IC50 (the concentration at which 50% virus inhibi-
tion is achieved) was more than 100-fold lower than its
anticoagulant threshold, suggesting a margin of safety for
use at concentrations capable of inhibiting infection [7].
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any medium, provided the original work is properly cited.Indeed, initial phase I and II clinical trials indicated that a
mixture of -a n dl-carrageenan (Carraguard) was safe
for vaginal application [8-12]. However, in phase III trials,
with time to seroconversion as the measure of efficacy,
Carraguard was shown to be ineffective as an anti-HIV-1
microbicide [13].
CS, which was formulated into a microbicide known as
Ushercell, was shown in vitro to have broad activity
against HIV-1, herpes simplex virus types 1 and 2, Neis-
seria gonorrhoeae,a n dChlamydia trachomatis [14].
After numerous clinical trials that established the safety
of Ushercell [15-20], two separate phase III trials were
initiated to assess its efficacy against HIV-1 transmission.
Both trials were halted when, in one trial, an increased
prevalence of HIV-1 infection was detected among
women using Ushercell [21]. Although subsequent ana-
lyses indicated that the apparent increase in HIV-1 infec-
tion was not statistically significant, neither trial
suggested any effectiveness of Ushercell as an inhibitor of
HIV-1 transmission [21,22].
As a result of the clinical failures of Carraguard and
Ushercell, efforts have been intensified to identify and
understand factors that may adversely affect the in vivo
efficacy of microbicides containing polyanionic com-
pounds. Such studies have revealed that seminal plasma
can decrease the antiviral activity of the polyanionic com-
pounds PRO2000 and CS [23] and that exposure to CS or
nonoxynol-9 (N-9) can disrupt an epithelial barrier and
increase HIV-1 passage through the epithelial barrier as
well as increase viral replication [24]. In studies designed
to reevaluate the antiviral activity of CS, enhancement of
HIV-1 infection by subefficacious concentrations of CS
was proposed as a contributor to the failure of Ushercell
[25]. Although the validity of the observed enhancement
was challenged [26,27], other groups have independently
observed similar effects of exposure to polyanionic
agents, including enhancement of TZM-bl cell infection
by low concentrations of Carraguard [28]; augmentation
of dendritic cell-mediated infection by Carraguard [28];
and “modest” increases in replication at low concentra-
tions of PRO2000 and the anionic, dendrimer-based
SPL7013. However, the effects noted in this latter study
did not appear to be limited to polyanionic molecules,
since a similar trend was also observed after application
of the entry inhibitor enfuvirtide [29].
Enhanced HIV-1 infection in the presence of low con-
centrations of a compound [25,28] suggests another vari-
able that may adversely affect microbicide efficacy during
clinical trials: product loss following topical application.
As a result of microbicide loss after application, concentra-
tions of the active agent in the female reproductive tract
will diminish over time [30]. Indeed, product leakage
(directly measured or reported by study participants) was
noted in phase I and phase II trials of carrageenan and CS
[15,31-34]. Once the concentrations of the active agents
have dropped sufficiently to render them ineffective as
microbicides, mechanisms that result in enhanced HIV-1
infection at low or negligible concentrations (such as those
described above) may prevail.
To investigate this hypothesis, we infected cells in
v i t r ow i t hH I V - 1a f t e re x p o s u r et oa n dr e m o v a lo fL C ,
CS, or dextran sulfate (DS). DS was included as a proto-
typical polyanionic compound with established activity
against HIV-1 [35-39]. This experimental design, which
has been used to investigate persistent or “memory”
antiviral activity [35,40-44], was used in these studies to
mimic the loss of these agents after topical vaginal
application. In experiments involving an HIV-1-suscepti-
ble indicator cell line and primary human immune cells,
HIV-1 infection was significantly enhanced by prior
exposure to these compounds. Furthermore, the timing
and degree of enhancement were dependent on target
cell, co-receptor phenotype, compound identity and
concentration, and the timing of the viral challenge.
These results suggest a role for the host cell in polya-
nion-dependent enhancement of HIV-1 infection.
Results
Polyanionic compounds effectively inhibit infection by
HIV-1 BaL and IIIB
To establish compound concentrations to be used in the
washout assays, P4-R5 MAGI cells and peripheral blood
mononuclear cells (PBMCs) were exposed to each
compound and simultaneously infected with HIV-1. Con-
current introduction of LC, CS, or DS resulted in concen-
tration-dependent inhibition of infection of the P4-R5
MAGI cell line by the R5 HIV-1 strain BaL (Figure 1A) or
the X4 strain IIIB (Figure 1B). Similarly, concentration-
dependent antiviral activity was observed in experiments
involving infection of primary human PBMC populations
with HIV-1 BaL (Figure 1C) or IIIB (Figure 1D). These
results were used to calculate IC50 and IC90 concentrations
for each compound (Table 1). Despite similarities in com-
pound charge and mechanisms of antiviral activity [45],
antiviral activities (as indicated by IC50 and IC90) appeared
to vary with target cell, compound, and virus co-receptor
usage (Table 1).
Preexposure to CS or LC enhances P4-R5 MAGI infection
by R5 HIV-1
In the washout infection experiments, antiviral com-
pounds were removed from the culture media before
introduction of virus. As a consequence, inhibitors that act
on viral binding and entry, like the polyanionic com-
pounds in question [46-48], were expected to be ineffec-
tive in this assay, because they would not be present at the
time of infection. Indeed, DS, when introduced at either
its IC50 (Figure 2A) or IC90 (Figure 2B), was effective only
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Page 2 of 13when present during the addition of virus ("S”). DS had no
effect on HIV-1 infection if it was added and then subse-
quently removed from the cells before introduction of
virus.
The activities of LC and CS in these experiments,
however, were unexpected. At its IC50,C Sw a s h o u t
resulted in a 60% increase in infectivity above the con-
trol level of HIV-1 infection when it was removed from
cells 1 h before infection by HIV-1 BaL but not when
its removal preceded infection by 2-7 h (Figure 2A).
The magnitude of enhancement appeared to be concen-
tration-dependent, because washout of CS at its IC90
subsequently caused a greater than 200% increase in
infection at 1 h after washout (Figure 2B). Furthermore,
the effect of the higher concentration of CS was time-
dependent: The higher concentration of CS caused
Figure 1 Polyanionic compound antiviral activity is demonstrated against both R5 and X4 HIV-1 in both P4-R5 MAGI cells and
peripheral blood mononuclear cells (PBMCs). P4-R5 MAGI cells were infected for 1 h with (A) HIV-1 strain BaL (CCR5 tropic) or (B) HIV-1 strain
IIIB (CXCR4 tropic) in the presence of dextran sulfate (DS), cellulose sulfate (CS), or l-carrageenan (LC). Infectivity remaining is expressed relative
to mock-treated, HIV-1-infected cells. PBMCs were incubated for 1 h with (C) HIV-1 strain BaL or (D) IIIB in the presence of DS, CS, or LC.
Infectivity remaining is expressed relative to mock-treated, HIV-1-infected cells. Data for this experiment are shown as mean values and
calculated standard deviations from two independent assays in which each concentration was examined in triplicate. Error bars represent
standard deviations.
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Page 3 of 13modest increases in infection (~40% increase) at 2, 3, 4,
5, and 7 h after washout and a larger increase (~140%
increase) at 6 h after washout.
Enhancement of HIV-1 infection by LC was also con-
centration- and time-dependent. Like DS, the removal
of LC at its IC50 had no subsequent effect on HIV-1
BaL infection (Figure 2A). However, washout of LC at
its IC90 caused significant increases in HIV-1 BaL infec-
tion that were first observed 2 h after washout (Figure
2B). The enhancement appeared to reach a plateau 4-6
h after compound removal (~140% increase) and was
somewhat less (~80% increase) at 7 h. Interestingly,
HIV-1 infection was still inhibited by LC at 1 h after
exposure.
To verify that the observed enhancement of infection
was not associated with changes in cell viability during
t h ec o u r s eo ft h ew a s h o u te x p e r i m e n t s ,P 4 - R 5M A G I
cell viability was assessed after washout of each com-
pound at its HIV-1 BaL IC50 and IC90 (because these
concentrations were, with one exception, higher than
the IIIB IC50 and IC90). No changes in P4-R5 MAGI cell
viability were observed out to 7 h after washout (Figure
2C, D). These results indicated that cell viability was not
altered by compound washout and was not a confound-
ing factor in these experiments.
Preexposure to CS or LC causes limited increases in P4-R5
MAGI infection by X4 HIV-1
To investigate the possibility that enhanced infection
subsequent to polyanionic compound exposure was
dependent on HIV-1 co-receptor usage, similar experi-
ments were performed using HIV-1 IIIB (Figure 3).
None of the compounds at their respective IC50 had any
effect on infections initiated after compound washout
(Figure 3A). In experiments involving each compound at
its IC90 (Figure 3B), LC was the only compound that
had an effect after washout (~60% increase at 2 h and
~30% increase at 6 h). A comparison of the effects of
compound exposure and washout on infection by HIV-1
BaL and IIIB suggests that co-receptor usage can affect
enhancement of HIV-1 infection by polyanionic
compounds.
Infection of primary human immune cells by HIV-1 BaL is
increased by preexposure and removal of polyanionic
compounds
Experiments similar to those described above were per-
formed to verify that the enhancement effects of polya-
nionic compounds could be observed during HIV-1
infection of primary human immune cell populations
and were not limited to a cell line susceptible to HIV-1
infection. In washout experiments involving HIV-1 BaL
infection of PBMCs, all three compounds caused varying
degrees of enhancement (Figure 4). In contrast to
experiments involving P4-R5 MAGI cells, DS washout
resulted in modest enhancements of HIV-1 infection,
with ~40% increases in infection at 2 and 7 h after
washout at its IC50 (Figure 4A) and ~30% increases at 2
and 6 h after washout at its IC90 (Figure 4B). CS wash-
out caused similar increases in HIV-1 infection at 1 and
7 h after washout at both concentrations, ranging from
~30% to ~70% over controls. Washout of LC at its IC50
caused increases in infection up to ~80% at 1, 3, 5, and
7 h after washout. However, LC at its IC75 (used in lieu
of an IC90, which could not be determined; see Table 1)
had no effect on HIV-1 BaL infection. As was demon-
strated using the P4-R5 MAGI cell line, compounds
a p p l i e dt oa n dr e m o v e df r o mP B M C sh a dn os u b s e -
quent effect on cell viability (Figure 4C, D).
Unlike experiments involving HIV-1 IIIB infection of
P4-R5 MAGI cells, washout experiments using PBMCs
and HIV-1 IIIB revealed more substantial increases in
HIV-1 infection (Figure 5). Washout of all three com-
pounds caused increases in HIV-1 infection relative to
Table 1 Calculated IC50 and IC90 for l-carrageenan, cellulose sulfate, and dextran sulfate (mg/mL)
P4-R5 MAGI Human PBMCs
HIV-1 BaL HIV-1 IIIB HIV-1 BaL HIV-1 IIIB
IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
LC 0.0037 (±
0.0009)
6.04
a (± 0.79) 0.064 (± 0.0084) 1.96 (± 0.077) 0.967 (± 0.53) 3.16
b (± 0.04) 0.061 (± 0.021) 0.87 (± 0.32)
CS 0.023 (± 0.0018) 1.24 (± 0.47) 0.003 (± 0.00047) 0.026 (± 0.00073) 0.0026 (±
0.0003)
0.0091 (±
0.0052)
0.014 (± 0.0034) 0.03 (± 0.0025)
DS 0.0058 (±
0.0011)
0.031 (±
0.012)
0.00052 (±
0.00011)
0.0028 (±
0.00015)
0.14 (± 0.045) 0.9 (± 0.18) 0.00056 (±
0.00017)
0.014 (±
0.0064)
CS cellulose sulfate, DS dextran sulfate, IC50 the concentration at which 50% virus inhibition is achieved, IC90 the concentration at which 90% virus inhibition is
achieved, LC l-carrageenan, PBMCs peripheral blood mononuclear cells
aExtrapolated concentration
bLC concentrations > 3.16 mg/mL could not be used due to excessive solution viscosity. Because 90% inhibition of HIV-1 BaL infection by LC in PBMCs was not
achieved, the LC IC75 (concentration that resulted in a 75% reduction of infection with respect to mock-treated, HIV-1-infected cells) was calculated and used in
the PBMC washout experiments
Presented data are from two independent experiments in which each data point was examined in triplicate
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Page 4 of 13Figure 2 Preexposure of P4-R5 MAGI cells to select polyanionic compounds results in enhancement of R5 HIV-1 infection. P4-R5 MAGI
cells were incubated for 1 h with (A)I C 50 or (B)I C 90 (the concentrations at which 50% or 90% virus inhibition is achieved, respectively) dextran
sulfate (DS), cellulose sulfate (CS), or l-carrageenan (LC). Following exposure, cells were washed thoroughly and either challenged immediately
with HIV-1 strain BaL for 1 h or supplemented with new medium for up to 6 h before infection with HIV-1 BaL (as described in Materials and
Methods). Infectivity remaining is expressed relative to mock-treated, HIV-1-infected cells. To assess possible changes in cell viability associated
with compound washout, P4-R5 MAGI cells were incubated for 1 h with (C)I C 50 and (D)I C 90 concentrations of DS, CS, or LC. The IC50 and IC90
for BaL inhibition were used because these concentrations were, with one exception, higher than the IIIB IC50 and IC90 (Table 1). Cells were
subsequently assessed for viability as described in Materials and Methods. Viability is expressed relative to mock-treated cells. Data for this
experiment are shown as mean values and calculated standard deviations from two independent assays in which each concentration was
examined in triplicate. Error bars represent standard deviations. **p ≤ 0.01, *** p ≤ 0.001.
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Page 5 of 13mock-exposed control infections. Although DS had no
effect on HIV-1 IIIB infection at its IC50 (Figure 5A),
washout of DS at its IC90 (Figure 5B) caused significant
increases in infection at 3, 4, 6, and 7 h after washout
(up to 113% increase at 6 h). Washout of the CS IC50
caused increases at all times after washout (up to 323%
increase at 7 h). Similar increases were observed after
washout of the CS IC90 (up to 228% increase at 7 h).
Enhancement following LC washout at both concentra-
tions was also observed. However, increases after wash-
o u to fL Ca ti t sI C 50 were generally higher, with
maximal enhancement at 2 h (237% increase) and 7 h
(323% increase).
Discussion
Investigations into the failures of N-9, C31G, Ushercell,
Carraguard, and PRO2000 continue to provide valuable
insights into factors that may adversely impact in vivo
microbicide efficacy. Studies of N-9, which began shortly
after the phase III trial failures [49], focused on cervi-
covaginal tissue damage and inflammation following
application of N-9. These studies implicated cervical tis-
sue damage [50], induced recruitment of immune cell
populations [50], and the production of proinflamma-
tory cytokines, such as interleukin (IL)-1b, IL-6, and IL-
8 [51-53] as explanations for the general failure of an
N-9-based microbicide, as well as increases in HIV-1
Figure 3 Exposure to l-carrageenan (LC) results in enhanced infection of P4-R5 MAGI cells by X4 HIV-1. P4-R5 MAGI cells were
incubated for 1 h with (A)I C 50 or (B)I C 90 (the concentrations at which 50% or 90% virus inhibition is achieved, respectively) of dextran sulfate
(DS), cellulose sulfate (CS), or LC. Following exposure, cells were washed thoroughly and either challenged immediately with HIV-1 strain IIIB for
1 h or supplemented with new medium for up to 6 h before challenge with HIV-1 IIIB (as described in Materials and Methods). Infectivity
remaining is expressed relative to mock-treated, HIV-1 infected cells. Data for this experiment are shown as mean values and calculated standard
deviations from two independent assays in which each concentration was examined in triplicate. Error bars represent standard deviations. **p ≤
0.01; *** p ≤ 0.001.
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Page 6 of 13Figure 4 Enhanced infection by HIV-1 BaL is observed in peripheral blood mononuclear cells (PBMCs) following exposure to select
polyanionic compounds. PBMCs were incubated for 1 h with (A)I C 50 or (B)I C 90 (the concentrations at which 50% or 90% virus inhibition is
achieved, respectively) dextran sulfate (DS), cellulose sulfate (CS), or l-carrageenan (LC). Following exposure, cells were washed thoroughly and
either challenged immediately with HIV-1 strain BaL for 1 h or supplemented with new medium for up to 6 h before challenge with HIV-1 BaL
(as described in Materials and Methods). Infectivity remaining is expressed relative to mock-treated, HIV-1 infected cells. To assess possible
changes in cell viability associated with compound washout, PBMCs were incubated for 1 h with (C)I C 50 and (D)I C 90 concentrations of DS, CS,
or LC. The IC50 and IC90 for BaL inhibition were used because these concentrations were, with two exceptions, higher than the IIIB IC50 and IC90
(Table 1). Cells were subsequently assessed for viability as described in Materials and Methods. Viability is expressed relative to mock-treated cells.
Data for this experiment are shown as mean values and calculated standard deviations from two independent assays in which each
concentration was examined in triplicate. Error bars represent standard deviations. *p ≤ 0.05; **p ≤ 0.01.
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Page 7 of 13infection after high-frequency application [54]. In con-
trast, factors that can be invoked to explain the failures
of the remaining microbicides have not yet been clearly
identified. It is apparent, however, that multiple
mechanisms are likely associated with the failures of
these microbicides.
The present in vitro studies, which were conducted to
examine microbicide loss following topical application
as a potential mechanism of microbicide failure, demon-
strated significant increases in HIV-1 infection following
the application and removal of the polyanionic com-
pounds DS, CS, and LC. Increases in infection, which
were observed in experiments using an HIV-1-suscepti-
ble cell line as well as primary human immune cells,
were found to be dependent on the target cell and co-
receptor usage by the infecting virus.
Although enhancement of HIV-1 infection following
polyanionic compound washout was clearly demon-
strated in the HIV-1 indicator cell line and in primary
human immune cells, specific results were not always
comparable between experiments using these two cell
populations. For example, LC washout at its IC50 had
no effect on HIV-1 IIIB infection of P4-R5 MAGI cells
(Figure 3A) but had a significant effect on HIV-1 IIIB
Figure 5 Enhanced infection by HIV-1 IIIB is observed in peripheral blood mononuclear cells (PBMCs) following exposure to select
polyanionic compounds. PBMCs were incubated for 1 h with (A)I C 90 or (B)I C 50 (the concentrations at which 50% or 90% virus inhibition is
achieved, respectively) dextran sulfate (DS), cellulose sulfate (CS), or l-carrageenan (LC). Following exposure, cells were washed thoroughly and
either infected immediately with HIV-1 strain IIIB for 1 h or supplemented with new medium for up to 6 h before infection with HIV-1 IIIB (as
described in Materials and Methods). Infectivity remaining is expressed relative to mock-treated, HIV-1-infected cells. Data for this experiment are
shown as mean values and calculated standard deviations from two independent assays in which each concentration was examined in triplicate.
Error bars represent standard deviations. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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Page 8 of 13infection of PBMCs (Figure 5A). Conversely, LC applica-
tion and removal at its IC90 (Figure 2A) resulted in
enhancement of HIV-1 BaL infection that increased
with post-exposure time in P4-R5 MAGI cells, whereas
t h ec o m p a r a b l ee x p e r i m e n ti nP B M C s( F i g u r e4 A )
demonstrated no HIV-1 BaL enhancement as a conse-
quence of LC pre-exposure. These apparently disparate
results are likely due to differences inherent in the cells
used in these experiments, including cell type (recombi-
nant cervical carcinoma cell line versus primary human
immune cell) and levels of receptor and co-receptor
expression (over-expressed on the P4-R5 MAGI cells).
In addition, a considerably lower multiplicity of infec-
tion (MOI) was used in the PBMC experiments. Any or
all of these factors could have affected the outcome of
these experiments. Future mechanism-focused experi-
ments may provide more definitive insights into the
underlying causes of these differences in outcome.
The effects of compound washout were also depen-
dent on the interval between compound removal and
introduction of virus, suggesting both immediate and
delayed mechanisms of enhanced infection. Enhance-
ment following a short (1- to 2-h) interval between
compound removal and infection suggests immediate
changes on the cell surface that enhance the early stages
of the HIV-1 replication cycle. Cell surface changes
initiated by microbicide exposure may be induced by
the retention of residual amounts of compound at the
cell surface or may persist after the compound has been
removed. Interactions between compound and cell sur-
face may enhance HIV-1 infection by favoring increased
viral binding and entry. Although numerous cell surface
molecules have been shown to participate in HIV-1
binding and entry, the impact of co-receptor usage on
enhancement implicates the involvement of the HIV-1
co-receptors CCR5 and CXCR4. However, the specificity
of this effect remains to be demonstrated.
Alternatively, enhancement after a relatively long (6-
to 7-h) interval after washout may suggest more indirect
mechanisms potentially involving signal transduction
events initiated by compound exposure. As evidence
that polyanionic molecules can initiate cell signaling cas-
cades, studies of innate immune activation using both
human and murine model systems have demonstrated
that carrageenan-induced inflammation requires signal-
ing through Toll-like receptor 4 [55,56] as well as
MyD88-dependent signal transduction [57]. Polyanion-
induced signal transduction and inflammation do not
appear to be limited to carrageenan, because DS has
been used for 20 years as an agent that reliably induces
experimental colitis in mice [58]. The demonstrated
activities of these polyanionic molecules raise the possi-
bility that delayed increases in HIV-1 infection observed
in the present studies were the result of signaling
initiated by DS, CS, or LC. Because of the time required
to initiate events downstream of compound-initiated sig-
nal transduction, the effects of this mechanism of
enhancement were not immediately evident but did
affect HIV-1 infection after a period of delay. A specific
target of polyanion-mediated signaling within the viral
replication cycle was not apparent from these results
and will need to be determined as part of future
investigations.
In the experiments involving primary human PBMCs
cells, observations of post-exposure, time-dependent
enhancement may also have been complicated by cell
population heterogeneity. Differences in the levels and
mechanisms of enhancement between T lymphocytes
and cells of monocyte lineage, which also differ greatly
in frequency within the total cell population, may have
biased the observed time-dependent enhancement of
HIV-1 infection relative to results obtained using the
homogeneous P4-R5 MAGI cell line. For example,
washout of LC at its BaL IC50 (Figure 4A) resulted in
enhanced infection at 1, 3, 5, 6, and 7 h post-exposure
and no enhancement at 2 and 4 h. This unusual pattern
of enhancement might be explained as an overlay of
time-dependent enhancement in T cells and monocytes/
macrophages, with different peaks of infection arising
from different HIV-1-infected cell populations. Further-
more, if compound-mediated intracellular signaling
results in the downstream release of cytokines and che-
mokines, the combined pattern of time-dependent
enhancement might be altered further because the
release of these soluble factors subsequently affects the
susceptibility to infection of uninfected neighboring
cells. The contributions of these factors will need to be
resolved in experiments using enriched target cell
populations.
The present results, as well as the results of previously
published studies, indicate that enhancement under
these conditions is also dependent on the identity of the
compound. This same assay design was previously used
to evaluate the antiviral activity of the biguanide-based
cationic entry inhibitor NB325 [35] as well as the activ-
ities of the polyanionic compounds poly (styrene-alt-
maleic acid) (alt-PSMA), poly(styrene sulfonate) (PSS),
and DS [59]. In direct contrast to the present studies,
which were focused on DS, CS, and LC, washout experi-
ments involving NB325 demonstrated persistent protec-
tion from infection by HIV-1 IIIB after compound
removal. Furthermore, studies involving alt-PSMA and
PSS demonstrated that enhancement of infection follow-
ing compound washout is not an effect that can be gen-
erally ascribed to polyanionic compounds. Although alt-
PSMA and PSS are similarly based on polystyrene back-
bones, they derive their polyanionic charges from differ-
ent moieties: maleic acid in the case of alt-PSMA and
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Page 9 of 13sulfonic acid in PSS. In washout assays, alt-PSMA
removal had no effect (enhancement or inhibition) on
HIV-1 infection, whereas PSS significantly increased
levels of infection relative to infection controls. The
results of our previous studies with DS are consistent
with previously published studies [29,60,61], which
demonstrated that DS could enhance HIV-1 infection in
monocyte-derived macrophages but not in CD4+ T lym-
phocytes [35]. The current experiments demonstrated
DS-mediated enhancement in PBMCs but not in P4-
CCR5 MAGI cells, presumably due to the inclusion of
monocyte-derived macrophages in the former cell
population.
How does one reconcile the present results with the
clinical failures of these compounds? Low concentra-
tions of compound will be achieved clinically by dilution
during sexual intercourse or time-dependent compound
leakage after application. Early phase I and phase II
safety and acceptability trials of carrageenan and CS
indicated, either through direct measurement or through
self-reporting by the women in the trials, that the pro-
duct leaked after application [15,31,34,62,63]. Leakage
would decrease the concentration of active compounds
available in the cervicovaginal environment, negating the
antiviral activity of the microbicide and potentially
favoring mechanisms that promote HIV-1 infection.
Therefore, the efficacy of a polyanionic compound such
as carrageenan or CS would be dictated by concentra-
tion. At high concentrations (as found after the initial
application of the microbicide product), the antiviral
activity of the compound will override any enhancing
activity. At low concentrations (or after the complete
loss of microbicide), the compound would be unable to
inhibit infection or offset the mechanisms that enhance
infection, and its overall effect would be to increase the
risk of infection. The activity of such a compound in a
clinical trial would be driven by variables that affect the
amount of product in the cervicovaginal tract, including
the elapsed time between product application and sexual
intercourse, dilution by seminal fluid, and the degree of
product leakage following application.
These results also suggest that plans to use carragee-
nan as a potential “active excipient” in formulations of
other active agents may not be advisable. Although the
safety of Carraguard was demonstrated in early clinical
trials and no enhancement was evident in the results of
the failed phase III trial [8-10,12,13,64], the possibility
remains that, under different circumstances, the use of
carrageenan in a formulated microbicide may result in
an increased risk of HIV-1 transmission. In light of
these results, the use of carrageenan in future microbi-
cide products should be carefully considered. These
results, however, do not broadly rule out the use of
polyanionic molecules in antiviral formulations, because
enhancement of HIV-1 infection does not appear to be
a universal property of polyanionic compounds. Previous
studies of the polyanionic alt-PSMA demonstrated that
its washout did not result in increased infection [37].
Conclusions
These studies, which demonstrate significant increases
in HIV-1 infection subsequent to application and
removal of l-carrageenan and CS, support plausible
explanations for the failures of microbicides formulated
from these compounds (and, perhaps, also PRO2000).
These investigations also emphasize the need for careful,
continued scrutiny of candidate microbicide compounds
for activities that may counter their efficacy against
HIV-1 infection and transmission.
Materials and methods
Compounds
DS (Dextralip 50, catalog # D8787, lot 71K1378) and l-
carrageenan (catalog #C-3889, lot 122K1444) were pur-
chased from Sigma-Aldrich (St. Louis, MO). CS (catalog
#AC17781-0500, lot A0219391) was purchased from
ACROS Organics (Morris Plains, NJ).
Cell line maintenance and primary cell isolation
P4-R5 MAGI cells (NIH AIDS Research and Reference
Reagent Program #3580) were maintained in Dulbecco
modified Eagle medium supplemented with 10% fetal
bovine serum, sodium bicarbonate (0.05%), antibiotics
(penicillin, streptomycin, and kanamycin at 40 μg/mL
each), and puromycin (1 μg/mL) [65]. Human PBMCs
were isolated from whole blood (Biological Specialty
Corp., Colmar, PA) using Ficoll-hypaque (Amersham
Biosciences, Piscataway, NJ) density gradient centrifuga-
tion and were subsequently cultured in RPMI (Roswell
Park Memorial Institute) medium supplemented with
10% fetal bovine serum, sodium bicarbonate (0.05%),
antibiotics (penicillin and streptomycin at 90 μg/mL
each), phytohemagglutinin-P (Sigma-Aldrich, catalog
#L8754 5 μg/mL), and IL-2 (NIH AIDS Research and
Reference Reagent Program #11697; 20 U/mL) [66].
After 48 h, PBMCs were washed and incubated for an
additional 24 h prior to infection in the absence of phy-
tohemagglutinin-P.
Assessing polyanionic compound inhibition of cell-free
HIV-1 infection
P4-R5 MAGI cells were cultured 18 h prior to infection
at a density of 1.2 × 10
4 cells/well in a 96-well plate.
Cells were incubated for 1 h with HIV-1 BaL (1.0 MOI)
or IIIB (0.1 MOI) (Advanced Biotechnologies, Inc.,
Columbia, MD) in the absence or presence of LC, CS,
o rD S .A f t e r1h ,c e l l sw e r ew a s h e d ,c u l t u r e df o ra n
additional 46 h, and subsequently assayed for HIV-1
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gene assay system for mammalian cells (Applied Biosys-
tems, Bedford, MA).
Human PBMCs, stimulated as described above, were
seeded at a density of 1 × 10
5 cells/well in a 96-well
plate. Cells were then incubated for 1 h with HIV-1 BaL
(0.6 MOI) or IIIB (0.3 MOI) in the absence or presence
of LC, CS, or DS. After 1 h, cells were washed and sub-
sequently cultured for 3 d, at which time the cells were
washed and supplied with new medium supplemented
with IL-2. The cells were then incubated for an addi-
tional 3 d and subsequently assayed for HIV-1 produc-
tion by determining the level of p24 core antigen in the
supernatant using an HIV-1 p24 antigen enzyme-linked
immunosorbent assay (ELISA) (ZeptoMetrix, Buffalo,
NY). Levels of infection were expressed relative to
mock-treated, HIV-1-infected cells.
Evaluating polyanionic compound anti-HIV-1 activity in a
washout assay
P4-R5 MAGI cells were incubated with each compound
for 1 h at its IC50 or IC90 (compound concentrations
that caused 50% or 90% reductions, respectively, in
infection relative to mock-treated, HIV-1-infected cells).
Cells were then challenged with HIV-1 BaL (1.0 MOI)
or IIIB (0.1 MOI) for 1 h at 37°C either concurrently
with compound incubation or up to 7 h after compound
removal ("washout” by three consecutive cell washes)
and incubation in new medium without compound. Fol-
lowing infection, cells were washed, incubated for
approximately 48 h, and then assayed for HIV-1 produc-
tion as described above. Stimulated PBMCs were
assessed for enhanced HIV-1 infection in a washout
assay similar to the P4-R5 MAGI cell-based assay with
HIV-1 BaL (0.6 MOI) and IIIB (0.3 MOI). Following
compound washout and subsequent infection, cells were
washed, incubated for 6 d, and then assayed for HIV-1
production using a p24 enzyme-linked immunosorbent
assay as described above.
Evaluating the effect of compound washout on cell
viability
P4-R5 MAGI cells were seeded at a density of 4 × 10
4
cells/well in a 96-well plate approximately 18 h prior to
experiment. Cells were then exposed to the indicated
concentrations of LC, CS, or DS for 1 h. Following the
exposure period, cells were washed and assessed for via-
bility using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay [67,68] of viability at the
indicated times after washout of the antiviral com-
pounds. In assays involving PBMCs, cells were seeded
at a density of 1 × 10
5 cells/well in a 96-well plate and
subsequently exposed to LC, CS, or DS for 1 h. Follow-
ing the exposure period, cells were washed and assessed
for viability using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium assay [69,70] of viability at the indicated times
after washout. In both assays, viability following com-
pound exposure was determined relative to mock-
exposed cells.
Data analyses
Data for all experiments are shown as mean values and
calculated standard deviations from two independent
assays in which each concentration was examined in tri-
plicate. IC50 and IC90 calculations were performed using
the Forecast function of Microsoft Excel. Statistical sig-
nificance was calculated in comparison with mock-
exposed cells (unless otherwise indicated) using a two-
tailed, unpaired Student t test.
Abbreviations
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